Abstract
The increasing burden of non-alcoholic fatty liver disease means that robust clinical pathways need to be established in primary care to identify patients with advanced fibrosis who may benefit from specialist management. This article summarises the current landscape of non-invasive liver fibrosis tests and discusses the outcomes and lessons learned from non-alcoholic fatty liver disease pathways that have been instigated around the UK. The inherent challenges of implementing such pathways are explored, along with developing technologies, such as artificial intelligence blood testing, which will likely play an important role in helping to identify and risk-stratify more patients with non-alcoholic fatty liver disease in primary care in the future.
| Original language | English |
|---|---|
| Pages (from-to) | 62-70 |
| Number of pages | 9 |
| Journal | British Journal of Health Care Management |
| Volume | 27 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2 Mar 2021 |
Bibliographical note
Funding Information:The publication of this article was supported by an unrestricted educational grant from Intercept Pharma UK & Ireland.
This paper presents independent research supported by the NIHR Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, and the NIHR Biomedical Research Centre at University College London Hospitals NHS Foundation Trust and University College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.
Publisher Copyright:
© 2021 MA Healthcare Ltd. All rights reserved.
Keywords
- Clinical pathways
- Healthcare costs
- Liver fibrosis
- Non-alcoholic fatty liver disease
ASJC Scopus subject areas
- Leadership and Management
- Health Policy
